These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 24509332

  • 1. Impaired renal function and bleeding in elderly treated with dabigatran.
    Berthelot E, Lavenu-Bombled C, Orostegui-Giron L, Desconclois C, Assayag P.
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):618-20. PubMed ID: 24509332
    [Abstract] [Full Text] [Related]

  • 2. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
    Kawabata M, Yokoyama Y, Sasano T, Hachiya H, Tanaka Y, Yagishita A, Sugiyama K, Nakamura T, Suzuki M, Isobe M, Hirao K.
    J Cardiol; 2013 Aug; 62(2):121-6. PubMed ID: 23680005
    [Abstract] [Full Text] [Related]

  • 3. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
    Owada S, Tomita H, Kinjo T, Ishida Y, Itoh T, Sasaki K, Horiuchi D, Kimura M, Sasaki S, Okumura K.
    Thromb Res; 2015 Jan; 135(1):62-7. PubMed ID: 25466835
    [Abstract] [Full Text] [Related]

  • 4. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S.
    Circulation; 2013 Jul 16; 128(3):237-43. PubMed ID: 23770747
    [Abstract] [Full Text] [Related]

  • 5. Dabigatran for stroke prevention in atrial fibrillation.
    Hohnloser SH, Diener HC.
    Hamostaseologie; 2012 Jul 16; 32(3):216-20. PubMed ID: 22739760
    [Abstract] [Full Text] [Related]

  • 6. Gastrointestinal bleeding under dabigatran.
    Stöllberger C, Lindner K, Finsterer J.
    J Postgrad Med; 2014 Jul 16; 60(2):192-3. PubMed ID: 24823522
    [Abstract] [Full Text] [Related]

  • 7. [Dabigatran therapy--perioperative management and interpretation of coagulation tests].
    Spannagl M, Bauersachs R, Debus ES, Gawaz M, Gerlach H, Haas S, Hach-Wunderle V, Lindhoff-Last E, Riess H, Schellong S, Schinzel H, Bode C.
    Hamostaseologie; 2012 Jul 16; 32(4):294-305. PubMed ID: 23114798
    [Abstract] [Full Text] [Related]

  • 8. Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S.
    Circulation; 2013 Nov 19; 128(21):2325-32. PubMed ID: 24081972
    [Abstract] [Full Text] [Related]

  • 9. Dabigatran: life-threatening bleeding.
    Prescrire Int; 2013 Feb 19; 22(135):41-3. PubMed ID: 23444501
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L.
    Circulation; 2014 Mar 04; 129(9):961-70. PubMed ID: 24323795
    [Abstract] [Full Text] [Related]

  • 11. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
    Berger R, Salhanick SD, Chase M, Ganetsky M.
    Ann Emerg Med; 2013 Apr 04; 61(4):475-9. PubMed ID: 23522810
    [Abstract] [Full Text] [Related]

  • 12. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.
    Wychowski MK, Kouides PA.
    Ann Pharmacother; 2012 Apr 04; 46(4):e10. PubMed ID: 22496474
    [Abstract] [Full Text] [Related]

  • 13. Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy.
    Finsterer J, Stöllberger C, Paul G, Bastovansky A.
    Cardiovasc Ther; 2013 Dec 04; 31(6):e111-4. PubMed ID: 24279385
    [Abstract] [Full Text] [Related]

  • 14. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
    Bouchard J, Ghannoum M, Bernier-Jean A, Williamson D, Kershaw G, Weatherburn C, Eris JM, Tran H, Patel JP, Roberts DM.
    Clin Toxicol (Phila); 2015 Mar 04; 53(3):156-63. PubMed ID: 25661675
    [Abstract] [Full Text] [Related]

  • 15. Bleeding with dabigatran (Pradaxa).
    Med Lett Drugs Ther; 2011 Dec 12; 53(1379-1380):98. PubMed ID: 22173427
    [Abstract] [Full Text] [Related]

  • 16. Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran.
    Getta B, Muller N, Motum P, Hsu D, Zebeljan D, Rosenfeld D.
    Br J Haematol; 2015 May 12; 169(4):603-4. PubMed ID: 25425051
    [No Abstract] [Full Text] [Related]

  • 17. Hemorrhagic complications associated with dabigatran use.
    Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, Hoffman RS, Nelson LS.
    Clin Toxicol (Phila); 2012 Nov 12; 50(9):854-7. PubMed ID: 22970730
    [Abstract] [Full Text] [Related]

  • 18. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GY.
    Am J Med; 2014 Jul 12; 127(7):650-656.e5. PubMed ID: 24530792
    [Abstract] [Full Text] [Related]

  • 19. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
    Okubo K, Kuwahara T, Takagi K, Takigawa M, Nakajima J, Watari Y, Nakashima E, Yamao K, Fujino T, Tsutsui H, Takahashi A.
    Am J Cardiol; 2015 Jun 15; 115(12):1696-9. PubMed ID: 25918026
    [Abstract] [Full Text] [Related]

  • 20. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.